Array
(
[actionDate] => 2012-05-24
[displayText] => Passed/agreed to in Senate: Passed Senate with amendments by Yea-Nay Vote. 96 - 1. Record Vote Number: 111.(text: CR S3568-3608)
[externalActionCode] => 17000
[description] => Passed Senate
)
Passed House
Array
(
[actionDate] => 2012-06-20
[displayText] => Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H3825-3861)
[externalActionCode] => 8000
[description] => Passed House
)
Resolving Differences
Array
(
[actionDate] => 2012-06-26
[displayText] => Resolving differences -- Senate actions: Senate agreed to House amendment to the bill (S. 3187) by Yea-Nay Vote. 92 - 4. Record Vote Number: 168.(consideration: CR S4626)
[externalActionCode] => 20500
[description] => Resolving Differences
)
To President
Array
(
[actionDate] => 2012-06-28
[displayText] => Presented to President.
[externalActionCode] => 28000
[description] => To President
)
Became Law
Array
(
[actionDate] => 2012-07-09
[displayText] => Became Public Law No: 112-144.
[externalActionCode] => 36000
[description] => Became Law
)
2.
S.Amdt.2111 — 112th Congress (2011-2012)Purpose:
To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market. Sponsor:Sen. Bingaman, Jeff [D-NM] (Submitted 05/17/2012) (Proposed 05/24/2012)
Latest Action: 05/24/12 Amendment SA 2111, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 28 - 67. Record Vote Number: 105. (All Actions)
2.
S.Amdt.2111 — 112th Congress (2011-2012)Purpose:To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.Sponsor:Sen. Bingaman, Jeff [D-NM] (Submitted 05/17/2012) (Proposed 05/24/2012)Latest Action:05/24/12 Amendment SA 2111, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 28 - 67. Record Vote Number: 105. (All Actions)
3.
S.Amdt.2108 — 112th Congress (2011-2012)Purpose:
To prohibit approval by the Food and Drug Administration of genetically engineered fish unless the National Oceanic and Atmospheric Administration concurs with such approval. Sponsor:Sen. Murkowski, Lisa [R-AK] (Submitted 05/17/2012) (Proposed 05/23/2012)
Latest Action: 05/24/12 Amendment SA 2108, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 46 - 50. Record Vote Number: 106. (All Actions)
3.
S.Amdt.2108 — 112th Congress (2011-2012)Purpose:To prohibit approval by the Food and Drug Administration of genetically engineered fish unless the National Oceanic and Atmospheric Administration concurs with such approval.Sponsor:Sen. Murkowski, Lisa [R-AK] (Submitted 05/17/2012) (Proposed 05/23/2012)Latest Action:05/24/12 Amendment SA 2108, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 46 - 50. Record Vote Number: 106. (All Actions)
